Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center Phase I clinical study for its in-house developed BET-BD2 inhibitor, HH3806, in Australia. This marks a significant milestone in the development of the drug, which targets the bromo and extra terminal (BET) binding domain 2 (BD2).
Profile of HH3806
HH3806 is a small molecule inhibitor that has demonstrated strong anti-tumor activity, good pharmacokinetic characteristics, safety, and druggability in pre-clinical studies. It represents a novel approach in cancer treatment, as there is currently no BET inhibitor approved for marketing anywhere in the world. However, one BET-BD2 inhibitor has already entered Phase I/II trials, highlighting the potential of this class of drugs.
Significance of the Clinical Trial
The initiation of the Phase I clinical trial for HH3806 is a crucial step in evaluating its safety and efficacy in humans. This global multi-center study will provide valuable data to support the further development of HH3806 as a potential treatment option for cancer patients. Haihe Pharmaceutical’s commitment to advancing innovative therapies underscores its role in driving progress in oncology research.-Fineline Info & Tech
